<SEC-DOCUMENT>0001295345-15-000020.txt : 20150203
<SEC-HEADER>0001295345-15-000020.hdr.sgml : 20150203
<ACCEPTANCE-DATETIME>20150203145130
ACCESSION NUMBER:		0001295345-15-000020
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20150203
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
FILED AS OF DATE:		20150203
DATE AS OF CHANGE:		20150203

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ZAXIS INTERNATIONAL INC
		CENTRAL INDEX KEY:			0000797542
		STANDARD INDUSTRIAL CLASSIFICATION:	BLANK CHECKS [6770]
		IRS NUMBER:				680080601
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-15746
		FILM NUMBER:		15570515

	BUSINESS ADDRESS:	
		STREET 1:		42 BEN ZVI STREET
		CITY:			RAMAT GAN
		STATE:			L3
		ZIP:			5224747
		BUSINESS PHONE:		972525795082

	MAIL ADDRESS:	
		STREET 1:		42 BEN ZVI STREET
		CITY:			RAMAT GAN
		STATE:			L3
		ZIP:			5224747

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INFERGENE CO
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8k02032015.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<html>

<body>
<div>

<hr SIZE="4" NOSHADE COLOR="#000000">

<hr SIZE="2" NOSHADE COLOR="#000000">

<p ALIGN="CENTER"><font FACE="TIMES NEW ROMAN, TIMES, SERIF" SIZE="4"><b>UNITED STATES<br>
SECURITIES AND EXCHANGE COMMISSION<br>
</b></font></p>

<p ALIGN="CENTER"><b><font FACE="TIMES NEW ROMAN, TIMES, SERIF" SIZE="3">Washington, D.C.
20549<br>
</font></b></p>

<p ALIGN="CENTER"><font SIZE="4" FACE="Times New Roman, Times, Serif">___________________<br>
<br>
<strong>FORM 8-K<br>
</strong>___________________</font></p>

<p align="center"><font size="3"><b>CURRENT REPORT</b> </font></p>

<p align="center"><font size="2"><b>Pursuant to Section&nbsp;13 or 15(d) of the Securities
Exchange Act of 1934</b> </font></p>

<p align="center"><font size="2">Date of report (date of earliest event reported):
February 3, 2015</font></p>

<p align="center">&nbsp;</p>

<p ALIGN="CENTER"><font face="TIMES NEW ROMAN, TIMES, SERIF" size="5"><b><u>ZAXIS
INTERNATIONAL INC.</u><br>
</b></font><font face="TIMES NEW ROMAN, TIMES, SERIF" size="1">(Exact Name of Registrant
as Specified in its Charter)</font></p>

<p ALIGN="CENTER">&nbsp;</p>

<p ALIGN="CENTER"><font size="2">Commission File No.: 0-15476</font></p>

<p ALIGN="CENTER">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" width="100%">
  <tr>
    <td width="50%" align="center"><font FACE="TIMES NEW ROMAN, TIMES, SERIF" SIZE="2"><u>Delaware</u></font></td>
    <td width="50%" align="center"><font FACE="TIMES NEW ROMAN, TIMES, SERIF" SIZE="2"><u>68-0080601</u></font></td>
  </tr>
  <tr>
    <td width="50%" align="center" bgcolor="#ffffff"><font size="1">(State of Incorporation)</font></td>
    <td width="50%" align="center" bgcolor="#ffffff"><font size="1">(I.R.S. Employer
    Identification No.)</font></td>
  </tr>
  <tr>
    <td width="50%" align="center"><font size="1">&nbsp; </font></td>
    <td width="50%" align="center"><font size="1">&nbsp; </font></td>
  </tr>
  <tr>
    <td width="50%" align="center">
	<font FACE="TIMES NEW ROMAN, TIMES, SERIF" SIZE="2"><u>42 Ben Zvi Street,
	Ramat Gan, Israel</u></font></td>
    <td width="50%" align="center">
	<font FACE="TIMES NEW ROMAN, TIMES, SERIF" SIZE="2"><u>5224747</u></font></td>
  </tr>
  <tr>
    <td width="50%" align="center" bgcolor="#ffffff"><font size="1">(Address of Principal
    Executive Offices)</font></td>
    <td width="50%" align="center" bgcolor="#ffffff"><font size="1">(ZIP Code)</font></td>
  </tr>
</table>

<p>&nbsp;</p>

<p ALIGN="CENTER"><font FACE="TIMES NEW ROMAN, TIMES, SERIF" SIZE="2">Registrant's
Telephone Number, including area code: (972) 52-579-5082</font></p>

<p ALIGN="CENTER">&nbsp;</p>

<p><font size="2">Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below): </font></p>

<p><font size="2" FACE="WINGDINGS">&#168</font><font size="2"> Written communications
pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425) <br>
</font><font size="2" FACE="WINGDINGS">&#168</font><font size="2"> Soliciting material
pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12)<br>
</font><font size="2" FACE="WINGDINGS">&#168</font><font size="2"> Pre-commencement
communications pursuant to Rule&nbsp;14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))<br>
</font><font size="2" FACE="WINGDINGS">&#168</font><font size="2"> Pre-commencement
communications pursuant to Rule&nbsp;13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
</font></p>

<hr SIZE="2" NOSHADE COLOR="#000000">

<hr SIZE="4" NOSHADE COLOR="#000000">
<p Style='page-break-before:always'>

<hr NOSHADE SIZE="5">

<font FACE="Times New Roman">

<p><font size="2"><b>Item 5.02 Departure of Directors or Certain Officers; Election of
Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain
Officers.</b><br><br>On February 3, 2015, the board of directors of Zaxis
International Inc. (the &quot;Registrant&quot;) appointed Oded Gilboa, age 41, a licensed CPA
in the United States and Israel, as the Registrant's Chief Financial Officer.
Since December 2013, Mr. Gilboa has also been serving as CFO of BreedIt Corp., a
reporting company under the Exchange Act.</font></p>
	<p><font size="2">Mr. Gilboa has over 18 years of experience in finance and public accounting,
	having served as a senior finance executive in the technology and biotech
	industries with responsibilities in corporate finance, accounting, strategic
	planning and operational and financial management. From 2010 through 2012,
	Mr. Gilboa served as the Revenue Accounting and Finance Manager of Mylan
	Specialty, a subsidiary of Mylan Inc. (NASDAQ: MYL), a global company
	focused on the development, manufacturing and marketing of prescription drug
	products. From 2007 through 2009, Mr. Gilboa was the Executive Director of
	Finance and US Controller of Taro Pharmaceuticals (NASDAQ:TAROF), a global
	pharmaceutical company. From 1998 through 2007 Mr. Gilboa held various
	financial positions with IDT Corporation (NYSE:IDT), a world-wide provider
	of telecommunications and media services, where in his most recent role he
	served as Director of Finance. Mr. Gilboa began his career in
	public accounting, auditing both public and private companies and holds a
	B.A in Economics and Accounting from Tel-Aviv University and an M.B.A. from
	Recanati Business School at Tel-Aviv University.</font></p>
	<font size="2">

	<font size="2" face="Times New Roman">

<p ALIGN="CENTER"><font size="2">SIGNATURES</font></p>

<p ALIGN="JUSTIFY"><font size="2">Pursuant to the requirements of the Securities Exchange
Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.</font></p>

<table ALIGN="CENTER" CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="100%">
  <tr VALIGN="TOP" BGCOLOR="#66FFFF">
    <td ALIGN="LEFT" WIDTH="100%" bgcolor="#FFFFFF"><div
    STYLE="MARGIN-LEFT: 11px; TEXT-INDENT: -10px"><u><p><font
    face="TIMES NEW ROMAN, TIMES, SERIF" size="2">/s/ Liron Carmel</font></u><br>
    <font size="2">CEO<br>
    	Liron Carmel<br>
    <i>&nbsp;&nbsp;Date: February 3, 2015</i></font></p>
    </div></td>
  </tr>
</table>

<p>&nbsp;</p>

<hr NOSHADE SIZE="5">
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
